Physical demand for diuretics declines in Russia for the first time in 4 years
08.10.2026
RetailDrug group

The Russian retail market for diuretics has encountered a significant structural change in demand, whereby, against the backdrop of overall sales growth for premium-price diuretics, physical consumption of a number of mass-market products declined for the first time in several years.

In the first eight months of 2026, retail sales (including the e-commerce segment with delivery to consumers) of diuretics (group C03А) in Russia amounted to 61.4 million packages worth RUB 13.3 billion (at retail prices, including VAT). During the period under review, the steady trend of increasing the market's financial volume continued, with ruble dynamics compared to January–August 2025 exceeding 11.8%, comparable to the growth rates of previous years.

The key feature of 2026 has been a change in the demand structure — for the first time in a four-year period, a decline in physical consumption has been recorded. While in 2024–2025 physical sales volume showed positive dynamics (+3.4% and +2.2%, respectively), based on the results of January–August 2026, the physical sales indicator in packages decreased by 1.5%.

According to the "Retail Audit of Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, the retail diuretic market shows a long-term trend characterized by an increase in the average cost of packages sold. This indicator increased from RUB 154 in 2023 to more than RUB 216 as of January–August 2026. A characteristic feature of the analyzed period is the synchronized rise in price of both foreign and locally produced products. Over the year, the average cost of a package of a domestic diuretic increased by 15.6%, reaching RUB 156, while imported analogues became more expensive by 13.7%, reaching RUB 305.

The undisputed leader of the analyzed segment in both monetary and physical terms is indapamide-based drugs. During the reporting period, this active ingredient accounted for approximately 26% of the group's total ruble sales volume and more than 44% of the total number of packages sold. The high demand for indapamide is ensured by a wide market offering: in the retail sector, it is sold by as many as 26 manufacturers, with Ozon Pharmacevtika playing a key role.

In total, based on the results of the first eight months of 2026, the retail segment of the Russian pharmaceutical market included 44 diuretic brands from 69 corporations. The absolute leader is unbranded Indapamide drugs, with a 20.3% share in monetary terms and 37.7% in physical terms. Second and third places are occupied by Veroshpiron from Gedeon Richter and unbranded Torasemide from 11 different companies (the main one being Medisorb). During the reporting period, these drugs accounted for 16.7% and 13.9% of the group's value sales volume.

During the analyzed period, the vast majority of participants in the top ten demonstrated positive dynamics in ruble sales, with the exception of the drugs Diuver from Teva and Arifon from Servier. The highest growth rates in the leading group have been recorded for the fourth consecutive year for the potassium-sparing diuretic Eplerenone, whose sales volume in ruble terms increased by 77% compared to January–August 2025. On the domestic market, this drug is represented by three manufacturers, the key one being the Russian company Pharmproject. Outside the TOP-10 ranking, the most pronounced growth in demand was demonstrated by the brand Lorvas (INN indapamide) from the Indian manufacturer Torrent. In the first eight months of 2026, the product's physical sales volume increased 45-fold, resulting in a 28-fold increase in total consumer spending on this drug.

Fig. Volume and Dynamics of Diuretic Sales (EphMRA Group C03A) on the Russian Retail Pharmaceutical Market, in 2022–2025 and January–August 2026

Leave your contact details and we will contact you

Close
Subscribe to our newsletter to always be up to date with the latest news
Select topics
All
Pharmaceuticals
Veterinary
Parapharmaceuticals
FMCG
I agree to the processing of personal data in accordance with the Personal Data Processing Policy and want to receive information materials